Sales & Marketing News | pharmaphorum

News

Pharma’s Medicare counteroffers are all in, says HHS

On the heels of a setback in pharma’s legal attempts to block Medicare’s new medicine price negotiation powers, the US government has said all drugmakers whose products ar

News

Bayer pays $310m for Euro rights to ATTR therapy acoramidis

Bayer has shored up its near-term pipeline by acquiring European rights to acoramidis from BridgeBio and Eidos Therapeutics, putting some big pharma muscle behind the ther

News

Judge knocks back AstraZeneca’s IRA challenge

AstraZeneca’s legal challenge to Medicare’s drug pricing negotiation powers has stumbled at the first hurdle in a federal court.

News

MHRA okays first drug under new mutual recognition scheme

A new formulation of Amgen’s cancer treatment Xgeva is the first to be approved in the UK under a new procedure designed to speed up access to new therapies.

News

Sandoz will pay $265m to settle price fixing case in US

Generic and biosimilar drug producer Sandoz has agreed a $265 million settlement that aims to put allegations of price-fixing brought in a Pennsylvania lawsuit behind

News

Viatris splashes out $350m on pair of Idorsia therapies

Viatris has made a play to expand its branded medicines business by licensing two late-stage drugs from Idorsia – for acute myocardial infarction (AMI) and systemic lupus

Pharma’s Medicare counteroffers are all in, says HHS

Bayer pays $310m for Euro rights to ATTR therapy acoramidis

Judge knocks back AstraZeneca’s IRA challenge

MHRA okays first drug under new mutual recognition scheme

Sandoz will pay $265m to settle price fixing case in US

Viatris splashes out $350m on pair of Idorsia therapies

Making direct-to-patient work, with Matt Wadyka

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks